Allianz Asset Management GmbH Increases Holdings in Solventum Corporation $SOLV

Allianz Asset Management GmbH lifted its holdings in shares of Solventum Corporation (NYSE:SOLV) by 330.7% in the second quarter, Holdings Channel.com reports. The fund owned 77,509 shares of the company’s stock after purchasing an additional 59,511 shares during the period. Allianz Asset Management GmbH’s holdings in Solventum were worth $5,878,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Cypress Capital Group boosted its stake in Solventum by 20.7% during the second quarter. Cypress Capital Group now owns 22,425 shares of the company’s stock worth $1,701,000 after acquiring an additional 3,850 shares in the last quarter. PrairieView Partners LLC lifted its holdings in shares of Solventum by 13.3% during the second quarter. PrairieView Partners LLC now owns 10,713 shares of the company’s stock valued at $812,000 after purchasing an additional 1,256 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in shares of Solventum in the 2nd quarter worth approximately $138,000. Aberdeen Group plc grew its stake in shares of Solventum by 8.4% in the 2nd quarter. Aberdeen Group plc now owns 23,220 shares of the company’s stock worth $1,761,000 after buying an additional 1,804 shares during the last quarter. Finally, Eastern Bank grew its stake in shares of Solventum by 28.4% in the 2nd quarter. Eastern Bank now owns 1,206 shares of the company’s stock worth $91,000 after buying an additional 267 shares during the last quarter.

Solventum Stock Down 0.2%

SOLV opened at $72.73 on Thursday. The stock has a market capitalization of $12.61 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 2.97 and a beta of 0.50. The firm has a 50 day moving average price of $72.64 and a 200-day moving average price of $72.02. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SOLV shares. UBS Group began coverage on Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target for the company. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research note on Tuesday, July 1st. Wells Fargo & Company raised their price target on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.